Position of the Transparency Council – Talvey (talquetamab)
At its meeting on 25 November 2024, the Transparency Council adopted position No. 129/2024 on the evaluation of Talvey (talquetamab) in the framework of the drug programme “Treatment of patients with plasmocytic myeloma (ICD-10: C90.0)”
Publication of the position >>